Drugs / Seroguard
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03640559 | May → Oct 2015 | — | Pharmasyntez | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03660787 | May 2017 → Jan 2018 | — | Pharmasyntez | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seroguard | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03640559 ↗ |
| Route | Other | “2.4 mL/kg IP” NCT03640559 ↗ |